8-K: QT Imaging Reports Strong Q1 2025 Results with $2.8 Million Revenue and Canon Manufacturing Agreement

QT Imaging announced positive Q1 2025 financial results, including $2.8 million in revenue, a 65% gross margin, and a new manufacturing agreement with Canon Medical Systems Corporation.

Summary

• QT Imaging reported its Q1 2025 financial results, showcasing a strong start to the year.
• The company generated $2.8 million in revenue, primarily from scanner sales, and achieved a gross margin of 65%.
• Six Breast Acoustic CTTM scanners were shipped during the quarter.
• A $10.1 million term loan with Lynrock Lake was secured to retire prior debt and provide working capital.
• QT Imaging entered into a contract manufacturing agreement with Canon Medical Systems Corporation to scale production.
• The company reported a net loss of $11.1 million, which includes significant debt extinguishment and issuance expenses.
• Non-GAAP Adjusted EBITDA was $(0.9) million for the quarter.
• The company's stock commenced trading on the over-the-counter market under the symbol QTIH on January 28, 2025, and was upgraded to the OTCQB Venture Market on March 11, 2025.
• QT Imaging reiterates its plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27 million in revenue in 2026 (shipment of 60 scanners).

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While there are positive aspects such as revenue growth, improved gross margin, and strategic partnerships, the significant net loss and delisting from Nasdaq temper the overall outlook. The company is making progress but faces challenges.

Positives

• Revenue increased to $2.8 million in Q1 2025, compared to $1.4 million in Q1 2024.
• Gross margin improved to 65% in Q1 2025, up from 56% in Q1 2024.
• The Lynrock Lake Term Loan provides $5.4 million for working capital after debt repayment.
• The Canon Manufacturing Agreement is expected to help scale production capabilities.
• The company successfully uplifted to the OTCQB Venture Market on March 11, 2025.
• Adjusted EBITDA improved to $(0.9) million in Q1 2025 from $(1.2) million in Q1 2024.

Negatives

• The company experienced a net loss of $11.1 million in Q1 2025, significantly higher than the $0.6 million loss in Q1 2024.
• The net loss includes $2.0 million in debt extinguishment expense and $6.6 million in debt issuance expense.
• The company's common stock was delisted from Nasdaq and is now trading on the OTCQB Venture Market.
• Net cash used in operating activities was $3.5 million in Q1 2025, compared to $6.0 million in Q1 2024.

Risks

• The company's ability to achieve its revenue targets of $18 million in 2025 and $27 million in 2026 depends on meeting minimum order quantities with NXC Imaging.
• The company's future performance is subject to risks related to commercializing its technology and scaling production.
• The company's ability to obtain and access financing in the future is a risk factor.
• The company's ability to pay its debt obligations as they come due is a risk factor.
• The company identified a material weakness in its internal controls over financial reporting.

Future Outlook

The company plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27 million in revenue in 2026 (shipment of 60 scanners).

Management Comments

• Dr. Raluca Dinu, QT Imaging Chief Executive Officer, stated, 'We had a strong start to 2025, shipping six Breast Acoustic CTTM scanners and generating $2.8 million in revenue with a 65% gross margin in the first quarter.'
• Dr. Dinu also mentioned, 'The successful closing of a $10.1 million term loan with Lynrock Lake significantly strengthens our balance sheet.'
• Dr. Dinu added, 'Were well-positioned to build on this momentum throughout the year.'

Industry Context

QT Imaging's focus on innovative body imaging systems using low-frequency sound waves positions it within the broader medical device industry, specifically in the diagnostic imaging sector. The agreement with Canon Medical Systems Corporation suggests a move towards greater market penetration and production scalability, aligning with industry trends of strategic partnerships for growth.

Comparison to Industry Standards

• Comparing QT Imaging's gross margin of 65% to other medical device companies, such as Hologic (which often reports gross margins in the 60-70% range), suggests competitive performance in terms of production efficiency.
• The revenue target of $18 million for 2025 is relatively small compared to established players like GE Healthcare or Siemens Healthineers, but represents significant growth potential for a company of QT Imaging's size.
• The shift to the OTCQB Venture Market after delisting from Nasdaq is a common path for companies facing compliance issues, but it typically results in lower trading volumes and potentially reduced investor interest compared to Nasdaq-listed peers.

Related Party Transactions

• The company received $500,000 from related persons in exchange for issuance of shares of common stock plus warrants for the purchase of common stock in a PIPE.

Stakeholder Impact

• Shareholders may be concerned about the delisting from Nasdaq and the significant net loss.
• Employees may be affected by the company's financial performance and strategic decisions.
• Customers may benefit from the company's improved production capabilities and product offerings.
• Suppliers may see increased demand as the company scales its production.
• Creditors are impacted by the new term loan and the company's ability to meet its debt obligations.

Next Steps

• The company intends to apply for listing on Nasdaq if in the future it is able to qualify to list under the Nasdaqs initial listing standards.
• The company expects to close the PIPE investment of approximately $200,000 no later than May 19, 2025.
• The company plans to deliver $18 million in revenue in 2025 (shipment of 40 scanners) and $27 million in revenue in 2026 (shipment of 60 scanners).

Key Dates

Keywords

QT Imaging, Financial Results, Breast Acoustic CTTM, Canon Medical Systems, Lynrock Lake, Revenue, Gross Margin, OTCQB, Delisting, Medical Device